Primidone in the treatment of the long QT syndrome: QT shortening and ventricular arrhythmia suppression.
We studied a family with the long QT syndrome. The initial case was in a patient who presented with seizures, ventricular fibrillation, and syncope. After a trial of conventional modalities of treatment including left stellate ganglionectomy, primidone (Mysoline) therapy was initiated. This drug has been successful in suppressing ventricular arrhythmias and shortening the QT interval over a 2-year follow-up period. Two additional family members with QT prolongation have been treated with primidone. During an 8-month follow-up, electrocardiographic and Holter recordings showed shortening of the QT interval.
D000293:Adolescent; D000328:Adult; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000235:genetics; D003645:Death, Sudden; D004562:Electrocardiography; D005260:Female; D005500:Follow-Up Studies; D006352:Heart Ventricles; D006801:Humans; D008297:Male; D011324:Primidone / Q000627:therapeutic use*; D012640:Seizures / Q000235:genetics; D013577:Syndrome
D011324:Primidone